Last updated: May 4, 2026. This article is updated monthly to reflect the latest FDA shortage data and pharmacy availability reports.
If you have been trying to fill a prescription for Ozempic, Wegovy, Mounjaro, or Zepbound and keep hearing "out of stock," you know how frustrating the GLP-1 medication supply chain can be. While the FDA officially declared the national semaglutide shortage resolved in February 2025, real-world availability at retail pharmacies remains inconsistent—particularly for specific dose strengths and in certain geographic regions.
This guide provides a real-time snapshot of the current availability status for every major GLP-1 medication, explains why certain doses remain difficult to find, and outlines your best options for uninterrupted access to treatment.
Current Availability Status (May 2026)
| Medication | FDA Shortage? | Pharmacy Availability | Notes |
|---|---|---|---|
| Ozempic | Resolved | Widely available | 2 mg dose may have intermittent delays |
| Wegovy | Resolved | Mostly available | Lower titration doses (0.25, 0.5mg) more available than maintenance |
| Mounjaro | Resolved | Widely available | All dose strengths generally in stock |
| Zepbound | Resolved | Available (pens + vials) | LillyDirect self-pay vials consistently available |
| Rybelsus (oral) | No shortage | Widely available | Oral tablet, no supply issues |
| Compounded GLP-1s | N/A | Available via 503A | 503B restricted; 503A patient-specific still legal |
Why Some Doses Are Still Hard to Find
Even though the FDA has declared the shortage resolved, "resolved" means the manufacturer has confirmed supply is adequate at the wholesale distribution level. It does not guarantee that your local CVS or Walgreens has the specific dose strength you need on the shelf right now.
Several factors create persistent, localized availability gaps:
- Demand Concentration: Maintenance doses (2.4 mg Wegovy, 15 mg Mounjaro) are consumed at much higher volumes than titration doses, creating demand imbalances.
- Pharmacy Ordering Limits: Wholesale distributors may cap the number of units a single pharmacy can order per week, creating artificial scarcity at high-volume locations.
- Geographic Variation: Urban pharmacies with high patient volumes experience stockouts more frequently than suburban or rural locations.
- Insurance Prior Authorization Delays: Even when medication is in stock, insurance prior authorization processes can delay fulfillment by 1–3 weeks.
Skip the Pharmacy Shortage
TelehealthFX ships directly from licensed pharmacies to your door. No pharmacy lines, no stockout frustration, no prior authorization delays.
Check AvailabilityYour Options When Medication Is Unavailable
- Switch Pharmacies: Call multiple pharmacies in your area. Independent pharmacies and specialty pharmacies often have better stock than chain locations.
- Ask About Alternative Dose Packaging: If your dose strength is out of stock, your prescriber may be able to adjust the prescription to use multiple lower-dose pens to achieve the same weekly dose.
- Consider Telehealth + Direct-Ship: Telehealth providers like TelehealthFX partner with licensed pharmacies that maintain dedicated inventory, bypassing retail pharmacy distribution bottlenecks entirely.
- Explore Oral Semaglutide (Rybelsus): If injectable supply is constrained, oral semaglutide tablets have not experienced the same shortage issues.
- Don't Pause Treatment: Gaps in GLP-1 therapy can trigger appetite rebound and weight regain. Read about what happens when you stop GLP-1 medication to understand the risks.
The Compounding Landscape Post-FDA Crackdown
The FDA's proposed 503B compounding ban has dramatically reshaped the compounded GLP-1 market. While large-scale outsourcing facilities are being shut down, patient-specific compounding through licensed 503A pharmacies remains legally available. For patients who need affordable, reliable access without fighting retail pharmacy shortages, compliant compounded GLP-1 therapy through a verified telehealth provider remains the most practical option.
Reliable, Uninterrupted Access
TelehealthFX maintains dedicated pharmacy partnerships to ensure your medication ships on schedule—every month, without gaps.
Start Your EvaluationFrequently Asked Questions
Is Ozempic still in shortage in 2026?
The FDA officially resolved the semaglutide shortage in February 2025. As of May 2026, Ozempic is widely available at most pharmacies, though the 2 mg dose strength may experience intermittent delays at high-volume locations.
What should I do if my pharmacy can't fill my GLP-1 prescription?
Call multiple pharmacies (including independents), ask your prescriber about alternative dose packaging, and consider telehealth providers with direct-ship pharmacy partnerships. Do not pause treatment—gaps can trigger appetite rebound.
Can I still get compounded semaglutide?
Yes, through licensed 503A pharmacies with a valid patient-specific prescription. The FDA's crackdown targets 503B outsourcing facilities, not traditional patient-specific compounding. Verify your provider is operating compliantly.
Don't Let Shortages Derail Your Progress
Access GLP-1 therapy through a provider that guarantees supply. No pharmacy lines, no stockouts.
Get StartedAcademic References & Clinical Citations
- U.S. Food and Drug Administration. (2025). FDA Drug Shortages: Semaglutide injection products. https://www.accessdata.fda.gov/scripts/drugshortages/
- U.S. Food and Drug Administration. (2025). FDA Drug Shortages: Tirzepatide injection products. https://www.accessdata.fda.gov/scripts/drugshortages/
- American Society of Health-System Pharmacists. (2026). ASHP Drug Shortage Resource Center. https://www.ashp.org/drug-shortages
- U.S. Food and Drug Administration. (2026). Drug Quality and Security Act: Compounding framework. https://www.fda.gov/drugs/human-drug-compounding/drug-quality-and-security-act